Quarter Comparison
Revenue
Operating Income
Gross Margin
Net Margin
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 ea030175701ex99-1.htm PRESS RELEASE ISSUED BY THE COMPANY ON AUGUST 12, 2026 Exhibit 99.1 Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update ● On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel
EX-99.1 2 ea030175701ex99-1.htm PRESS RELEASE ISSUED BY THE COMPANY ON AUGUST 12, 2026 Exhibit 99.1 Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update ● On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication ● Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty ● Three new independent Directors join Longeveron’s Board of Directors ● Company to host conference call and webcast today at 4:30 p.m. ET MIAMI, Fla., August 12, 2026 -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnolo...
Source
Exhibit EX-99.1
0001213900-26-088365
Filed August 12, 2026 at 8:14 PM UTC. The figures above are from the audited statements, not from this release.